**Supplementary Figure 2. Viability of undifferentiated iPSCs from patients with DM and non-DM individuals.** (A) CCK-8 assay graphs of iPSCs from patients with DM and non-DM individuals after incubation with different concentrations and for different exposure durations of Tac treatment. (B) Calculated area under the curve graphs from A. (C) Insulin messenger RNA (mRNA) levels for PP cells from patients with DM and non-DM individuals treated with 60-μg/mL Tac. Data are expressed as mean ± standard error.

AUC, area under the curve; CCK-8, Cell Counting Kit-8; DM, diabetes mellitus; iPSC, induced pluripotent stem cell; Tac, tacrolimus.